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Abstract
Introduction: Smoking during pregnancy remains common, and the English National Health 
Service (NHS) has recently been directed to prioritize providing cessation support for pregnant 
women. We investigated the impact on prescribing of stop smoking treatments to pregnant women 
of the 2013 transfer of public health budgets from the NHS to administrative authorities respon-
sible for local social care and other nonhealth services (local authorities).
Methods: We used data from the Clinical Practice Research Datalink and Hospital Episode Statistics 
to determine annual proportions (2005–2017) of women who smoked during pregnancy and who 
were prescribed, at least once before childbirth, (1) any NRT and (2) long- and short-acting NRT 
together (dual NRT). Segmented regression was used to quantify the impact of the 2013 transfer of 
smoking cessation budgets to local authorities, assessing changes in the level and the trend of the 
proportions post-2013 compared with pre-2013.
Results: We identified 84 539 pregnancies in which women were recorded as smoking; any NRT 
was prescribed in 7.9% (n = 6704) and dual NRT in 1.7% (n = 1466). Prescribing of any NRT was 
declining prior to 2013 at an absolute decrease of −0.25% per year, but the rate of decline signifi-
cantly increased from 2013 onwards to −1.37% per year. Prescribing of dual NRT was increasing 
prior to 2013 but also decreased post-2013.
Conclusions: These findings suggest that transferring responsibility for English Smoking 
Cessation Services from the NHS to local authorities adversely affected provision of cessation 
support in pregnancy. Consequently, some women may have been denied access to effective ces-
sation treatments.
Implications: Women who smoke during pregnancy may be being denied potentially effective 
means to help them quit, contrary to NICE guidance, at what can be a teachable moment with 
substantial immediate and longer-term health benefits for woman and their unborn child, and eco-
nomic benefits for the NHS. When the organizations responsible for offering smoking cessation 
support are changed, health systems should consider potential adverse effects on the delivery of 
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Introduction
Globally, smoking in pregnancy remains common.1 In England in 
the year to March 2020, 10.4% of women smoked at the time of 
delivery2 and in 2015, 23.3% of UK women were estimated to have 
smoked (any frequency/quantity) in pregnancy.1 Smoking in preg-
nancy is associated with increased risks of many adverse pregnancy, 
birth, and child outcomes3 and children of smoking mothers are 
twice as likely to themselves start smoking.4 Reducing smoking in 
pregnancy is likely to have a major impact on medical resource use 
and the English NHS has recently been directed to prioritize pro-
viding cessation support for pregnant women.5
Nicotine replacement therapy (NRT) can assist smoking ces-
sation in pregnancy,6 though due to insufficient data on safety, its 
use is suggested where smoking cessation without NRT fails.7(p26) 
Adherence with NRT in pregnancy is poor, potentially because 
nicotine metabolism is faster in pregnancy and standard doses of 
NRT are thus less likely to ameliorate withdrawal symptoms.8 Dual 
NRT, combining a nicotine patch (for a steady background nicotine 
supply) with a fast-acting NRT like gum (to “top-up” the nicotine 
dose as needed), may be more likely to lead to cessation than mono 
NRT,9 though current NHS guidelines for supporting smoking ces-
sation in pregnancy do not mention use of dual NRT as a treatment 
option.7(p26)
A recent British Lung Foundation report suggests that, since 2013 
when public health budgets were transferred from the NHS to local 
authorities, primary care prescribing of stop smoking treatments to 
people who smoke may have declined.10 This report used data on 
items dispensed and estimates of population size and smoking preva-
lence and did not formally quantify the impact of funding changes 
using robust statistical methods. Hence, here we use interrupted time 
series analysis with data routinely recorded in primary care to inves-
tigate trends in primary care prescribing of NRT to pregnant women 
before and after 2013.
Methods
We used data from all (n = 398) general practices in England who 
contribute data to the Clinical Practice Research Datalink (CPRD)11 
and which are linked to secondary care data from Hospital Episode 
Statistics (HES),12 allowing us to identify mothers and their chil-
dren. Women were included in the study cohort if they had one or 
more pregnancies resulting in a live birth or stillbirth recorded in 
CPRD-HES between January 1, 2005 and December 31, 2017 and 
if they were aged 15–49 at the time of birth. Women were identified 
as smoking in pregnancy if they had a diagnostic code indicating 
current smoking, or a prescription for a smoking cessation medica-
tion, recorded at least once during gestation. Prescriptions for NRT 
were identified using relevant Multilex drug codes. Dual NRT was 
defined as prescription of a long-acting transdermal nicotine patch 
and a short-acting formulation (eg, gum, lozenge, inhalator, tablet, 
or spray) on the same day.
By year of delivery, we determined annual proportions of women 
who smoked during pregnancy who were prescribed (1) any NRT at 
least once during pregnancy and (2) dual NRT at least once during 
pregnancy; by definition, these groups were not discrete—women 
who were prescribed dual NRT were a subset of those prescribed 
any NRT. We used segmented regression13 to quantify the impact on 
each data series of the 2013 transfer of smoking cessation budgets 
to local authorities, assessing changes in the level and the trend of 
the data post-2013 compared with pre-2013. We used a backward 
elimination approach to build parsimonious models and checked for 
autocorrelation by visual inspection of the autocorrelation function 
of the model residuals and by conducting a Portmanteau test using a 
significance level of p < .05.
Data management and analyses were conducted using Stata 16 
(Stata Corp, College Station, TX). CPRD-HES data received eth-
ical approval from a National Research Ethics Service Committee 
(NRES) for data collection and subsequent observational research 
using anonymized data; individual studies do not require further 
separate ethical approval. The protocol for this project was ap-
proved by the CPRD Independent Scientific Advisory Committee 
(reference: 16_151).
Results
We identified 339 875 pregnancies during the study period, and 
in 84 539 (24.9%), the mother was recorded as smoking; this 
prevalence was stable at an average 25.6% for the first 5 years 
of the study period before declining to 21.3% in 2017. Overall, 
any NRT was prescribed in 7.9% (n = 6704)  and dual NRT 
in 1.7% (n = 1466), of pregnancies where the mother smoked. 
Figure 1 shows changes over time in the percentage of pregnan-
cies where the mother smoked where any NRT and dual NRT 
were prescribed.
Table 1 presents results from the interrupted time series analysis 
showing the year-on-year absolute change in the prevalence of pre-
scribing of any NRT and dual NRT between 2005 and 2012, the 
absolute change in trend from 2012 to 2013, and the year-on-year 
absolute change in prescribing from 2013 onwards.
Findings show that prescribing any NRT to pregnant women 
who smoked was declining prior to 2013 at a rate of approximately 
one quarter of a percentage point per year. However, the rate of de-
cline increased from 2013 onwards such that from 2013 to 2017 
prescribing decreased by an absolute magnitude of 1.37% per year. 
Prescribing of dual NRT was increasing prior to 2013, but there was 
a similar change in trend such that from 2013 to 2017 prescribing 
decreased by an absolute magnitude of 0.42% per year.
Figure 1. Prevalence of prescribing of any nicotine replacement therapy 
(NRT) and dual NRT to pregnant smokers by year of delivery (dashed vertical 
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Discussion
Using data from a large, representative data set, we have shown a de-
cline in primary care prescribing of any NRT to pregnant women who 
smoke, with the rate of decline increasing since 2013. Prescribing of 
dual NRT, potentially a more effective means of cessation support than 
mono NRT, was increasing up to 2012, but this too has since decreased. 
This is despite smoking in pregnancy remaining a significant problem; 
within our data set, at the end of the study period, approximately one 
in five women smoked during pregnancy.
Though we cannot assume causation, the timing of declines in 
prescribing suggests an association with the 2013 funding changes. 
It is possible that some of the decline in prescribing of NRT is related 
to increased use of electronic cigarettes; the number of e-cigarette 
users in the general population in Great Britain increased from 0.7 
million in 2012 to 2.9 million in 2017.14 However, in the UK, use 
of e-cigarettes by pregnant women is not particularly widespread; a 
2017 survey found that only 5% of pregnant women reported any 
vaping during pregnancy and only around 1% reported exclusive 
vaping (ie, they had stopped smoking).14 It seems unlikely, therefore, 
that vaping behavior would have had a substantial impact on preg-
nant women’s propensity to use NRT and hence, on primary care 
prescribing. Nevertheless, research investigating any relationships 
between smoking, e-cigarette, and NRT use by pregnant women, 
including impacts of longitudinal changes in prevalence of use and 
potential trade-offs between e-cigarette use and primary care NRT 
prescribing, would be informative.
It is also possible that some of the decline in prescribing may 
have been offset by increased referral of smokers to the post-2013 
local authority-commissioned Stop Smoking Services (SSS). We did 
not have data available on direct referrals from primary care to SSS. 
However, data on the number of people setting a quit date in SSS 
based in primary care, community and pharmacy settings (which to-
gether comprise over 90% of all quit dates set with SSS) show a 
steady decline from the 2011/2012 financial year to 2016/2017. For 
example, 332 011 people set a quit date in primary care-based SSS 
in 2011/2012 which fell to 115 460 in 2016/2017; declines were of 
a similar magnitude in community-based and pharmacy-based SSS.15 
These figures suggest there was an overall decline in the use of SSS 
and do not provide any support for the notion that referrals from 
primary care increased.
Around 20% of SSS provide NRT to pregnant women via FP10 
prescriptions issued through primary care,16 and this figure has not 
changed substantially over time (R Thomson, personal communi-
cation, February 3, 2021). The number of pregnant women who 
set a quit date with SSS fell from 26 080 in 2011/2012 to 15 216 
in 2016/2017,15 and we estimate that this would result in approxi-
mately 2000 (ie, 26 080  − 15 216  × 0.2) fewer women annually 
being prescribed NRT through SSS via FP10 prescription. This is 
substantially less than the overall decline in prescribing of NRT in 
primary care and suggests that there must also be a decline in direct 
prescribing of NRT by general practitioners, outwith any prescribing 
through SSS. Since 2013, many local authority-commissioned SSS 
have been cut or decommissioned.10,17 It is possible that where there 
is no local SSS to which general practitioners can refer pregnant 
women there is a reduced stimulus for discussion of smoking cessa-
tion and thus less direct prescribing of NRT. This may indicate an 
indirect effect of decommissioning SSS on smoking cessation activity 
and hence on NRT prescribing in primary care too.
Given the lack of evidence to support alternative explanations for 
the reduction in primary care NRT prescribing to pregnant women, 
it seems most likely that this is related to the transfer of public health 
budgets to local authorities. There is little available data on how the 
specific provision of LA SSS support to pregnant women might have 
changed in this period. Anecdotal reports suggest that some local au-
thorities have prioritized providing SSS support to pregnant women 
who smoke, as well as to other disadvantaged groups. However, it 
seems likely that there has been a parallel decrease in SSS support 
for pregnant smokers and this has been reflected in reduced primary 
care prescribing.
Therefore, contrary to NICE guidance, some pregnant women, 
unable to access NRT through either primary care or a specialist 
SSS, may have been denied access to effective cessation support.7 
Future NHS provision of such support, advocated in the NHS Long 
Term Plan, may improve this situation.5 However, maximal imme-
diate and longer-term health benefits for women and their unborn 
children, and economic benefits for the NHS, are unlikely to follow 
this investment unless the decline in local authority provision of stop 
smoking support for pregnant women is reversed.
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Table 1. Year-on-Year Percentage Changes in Prescribing Before and After the 2013 Transfer of Smoking Cessation Budgets to Local 
Authorities
Medication
Absolute annual percentage change in 
prescribing 2005–2012 (95% CI)
Change in trend from  
2012 to 2013 % (95% CI)
Absolute annual percentage change in 
prescribing 2013–2017a (95% CI)
Any NRT −0.25 (−0.36 to −0.15), p < .001 −1.12 (−1.35 to −0.88), p < .001 −1.37 (−1.52 to −1.21), p < .001
Dual NRT 0.34 (0.26 to 0.42), p < .001 −0.76 (−0.93 to −0.60), p < .001 −0.42 (−0.53 to −0.31), p < .001
CI, confidence interval; NRT, nicotine replacement therapy.
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